QUIDEL CORPORATION (NASDAQ:QDEL) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure.
In response to the ex parte application of Quidel Corporation (the “Company”) to stay the California State Court’s December 7, 2018 order granting a motion for summary adjudication and for an extension to file a writ petition in the Company’s ongoing litigation with Beckman Coulter Inc., on December 18, 2018, the Court issued a minute order granting a stay of his December 7, 2018 order until the California Court of Appeal decides whether to grant or deny stay. In addition, the Court granted a 10-day extension to file a writ petition. The Company has until January 18, 2019 to file a writ petition.
The Company will post a copy of the Court’s December 18, 2018, minute order on its website at http://ir.quidel.com, and, to the extent permitted by any applicable Protective Order, intends to post each additional written order of the Court in this matter to its website after it is available to the Company. Investors and others should note that the Company may disclose important information regarding this litigation matter on its website in posting these orders. Accordingly, investors should monitor the Company’s website in addition to its press releases, filings with the Securities and Exchange Commission, and investor conference calls and webcasts for updates on the litigation.
About QUIDEL CORPORATION (NASDAQ:QDEL)
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The Company’s diagnostic testing solutions primarily include applications in infectious diseases, women’s health and gastrointestinal diseases. It sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics and wellness screening centers. It markets its products in the United States through a network of national and regional distributors and a direct sales force. Internationally, it sells and markets primarily through distributor arrangements. Its diagnostic solutions are used in the detection and diagnosis of many critical diseases and other medical conditions, including autoimmune diseases, bone health and thyroid diseases. It provides diagnostic testing solutions under various brand names, including Quidel, QuickVue+ and Thyretain.
